You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Haleon plc purchased 12,572,956 ordinary shares of £0.01 each, to be held as treasury shares under its share buyback programme announced on 29 October 2026.
Haleon disclosed that Bláthnaid Bergin purchased 7,670 ordinary shares at £3.242 per share on 30 October 2026 through the London Stock Exchange.
As at 31 October 2026, Haleon plc had issued 8,808,341,409 ordinary shares of £0.01 each, including 16,238,543 treasury shares, leaving 8,792,102,866 ordinary shares with voting rights.
Haleon plc purchased 4,492,636 ordinary shares of £0.01 each on 29 October 2026 and 30 October 2026 under its share buyback programme, to be held as treasury shares; 16,238,543 treasury shares left 8,792,102,866 ordinary shares with voting rights.
Haleon said Q3 was below expectations, with weak North America and Europe plus a Centrum OTC classification issue in China weighing on results. It retained its 4% to 6% growth ambition, but expects the China issue to continue through 2027.
Useful current figures from the complete screener profile.
Hims & Hers closed at $32.84, off 50.4% from its 52-week high, with short interest at 26.4% of shares outstanding and the steepest positioning in the comp set against a +59.0% TTM revenue base and a 10%–12% full-year adjusted EBITDA guide — the next quarter decides whether the multiple re-rates with subscriber growth or compresses further on the 6% ARPU slide.
A $413.3M small-cap MCM franchise that has signed a $140M Canada agreement, a $54M ASPR award, and an ACAM2000 modification while net leverage fell to 1.9x and a $50M buyback was reauthorized — yet the equity is the worst YTD performer in the peer set with 19.9% short interest, leaving the print of the next four quarters to test whether the international MCM pivot can offset the Narcan generics drag.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
HLN
this stock
Haleon plc
|
$40.25B | -9.3% | — | — | 0.3% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$68.47B | +37.5% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$53.23B | +10.1% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$51.92B | +42.6% | +4.3% | 101.1 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| HLN | +0.3% | -9.5% | -0.8% | +5.9% | -9.3% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -2.3% | -8.3% | -1.3% | +6.1% | -19.9% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
